Drug-buying agency Pharmac of New Zealand is making certain changes to asthma medication management next week and it says these changes are bound to benefit a significant number of moderate to severe asthma sufferers.
Some of the changes include widening the access to asthma control medications as well as increasing the choice available to patients by introducing a new aerosol inhaler.Pharmac medical director, Dr Peter Moodie stressed that these changes will widen the access to long-acting inhalers for 15,000 more asthma sufferers.
The new combination inhaler Seretide will also help sufferers, he said. This drug shows exactly how many doses are left in each canister and is a leading drug in Australia.
